Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985;8(3-4):155-65.
doi: 10.1007/BF01815440.

Corticotropin- and growth hormone-releasing factor (CRF and GRF) in the diagnosis of hypothalamo-pituitary diseases

Corticotropin- and growth hormone-releasing factor (CRF and GRF) in the diagnosis of hypothalamo-pituitary diseases

K von Werder et al. Neurosurg Rev. 1985.

Abstract

The recently discovered releasing factors for ACTH and growth hormone, CRF and GRF, have stimulated our understanding of the hypothalamo-pituitary physiology and pathophysiology. Whereas CRF, a 41 amino-acid residue peptide, seems to be a useful additional tool in the differential diagnosis of Cushing's syndrome, GRF, a 44 amino-acid residue peptide, seems to be of little value in the diagnosis of active acromegaly. However, both releasing factors are useful in the follow-up of these two hypersecretory diseases after neurosurgical treatment. In addition, the measurement of CRF and GRF activity by radioimmunoassay in the peripheral circulation will be of great importance in making the diagnosis of ectopic CRF- and GRF-secretion, syndromes which have been appreciated only in recent years. Furthermore, CRF and GRF-stimulation tests are useful in elucidating the cause of anterior pituitary failure and GRF may be of benefit for the treatment of pituitary dwarfism. However, it has to be stressed that the results of the new CRF and GRF tests can only be interpreted together with results of other established pituitary function tests and the neuroradiological evaluation of the hypothalamo-pituitary area.

PubMed Disclaimer

Similar articles

References

    1. Physiol Rev. 1948 Apr;28(2):139-79 - PubMed
    1. J Endocrinol Invest. 1984 Jun;7(3):185-91 - PubMed
    1. J Clin Endocrinol Metab. 1984 Jul;59(1):1-6 - PubMed
    1. J Clin Endocrinol Metab. 1984 Apr;58(4):758-60 - PubMed
    1. J Clin Invest. 1984 Jul;74(1):96-103 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources